Peter Seongwoo Hwang

This inventor holds 19 USPTO granted patents and 9 published patent applications, plus 5 CIPO patents and 5 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Ptc Therapeutics, Inc.. Active years: 2010-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter Seongwoo Hwang. Retrieved from https://idiyas.com/inventor/peter-seongwoo-hwang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 9)

% Patents Active = 42.1

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 129(Granted Patents)

Company Filing History:

19 out of 186

Ptc Therapeutics, Inc.

patents

Years Active: 2010-2021

Loading Chart...

Areas of Expertise:

Crystalline Forms

Oxadiazole Compounds

Benzoic Acid

Cancer Treatment

Functional Protein

Hepatitis C

Bioassays

Substituted Tetrahydro Beta-Carbolines

Processes for Preparation

Compositions

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10959988 - Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the treatment of disease (2021-03-30),

2. 10947231 - Processes for the preparation of substituted tetrahydro beta-carbolines (2021-03-16),

3. 10300047 - Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the treatment of disease (2019-05-28),

4. 10028939 - Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the treatment of disease (2018-07-24),

5. 9351964 - Methods for treating cancer and non-neoplastic conditions (2016-05-31),

6. 9309206 - Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4] oxadiazol-3-yl]-benzoic acid (2016-04-12),

7. 9289398 - Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith (2016-03-22),

8. 8748625 - Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid (2014-06-10),

9. 8691511 - Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and their use in bioassays (2014-04-08),

10. 8394966 - Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid (2013-03-12),

11. 8367841 - Processes for the preparation of 1,2,4-oxadiazole benzoic acids (2013-02-05),

12. 8101641 - Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof (2012-01-24),

13. 8013006 - Methods for treating hepatitis C (2011-09-06),

14. 7973069 - Methods for treating hepatitis C (2011-07-05),

15. 7868037 - Methods for treating hepatitis C (2011-01-11),

Title: The Innovative Journey of Peter Seongwoo Hwang

Introduction: Peter Seongwoo Hwang, a talented inventor based in Edison, NJ (US), has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Peter Seongwoo Hwang holds several patents in various technological domains, showcasing his versatility and creativity in innovation.

Career Highlights: Throughout his illustrious career, Peter Seongwoo Hwang has demonstrated a keen ability to identify gaps in the market and develop innovative solutions to address them. His passion for technology and commitment to excellence have earned him a reputation as a visionary inventor.

Collaborations: Peter Seongwoo Hwang has collaborated with leading tech companies, research institutions, and universities to further his research and bring his inventions to life. His collaborative spirit and dedication to teamwork have been instrumental in his success as an inventor.

Conclusion: Peter Seongwoo Hwang's relentless pursuit of innovation and his remarkable contributions to the field of technology have solidified his position as a respected inventor in the industry. His inventive spirit continues to inspire future generations of inventors to push the boundaries of what is possible.

Profile summary based on public USPTO records.